VIS-101 Shows Safety, Rapid Efficacy in Wet AMD

Why It Matters

VIS‑101 could markedly reduce injection frequency while improving outcomes, reshaping the competitive landscape for wet AMD therapies and offering patients a more convenient treatment regimen.

Key Takeaways

• Phase 2a shows >10‑letter visual gain.
• Median CST reduction 100‑150 µm.
• Two‑thirds re‑treatment free at 4 months.
• Favorable safety, no dose‑limiting toxicity.
• Phase 2b slated H2 2026; Phase 3 2027.

Pulse Analysis

The wet age‑related macular degeneration market has been dominated by anti‑VEGF monotherapies, which require frequent intravitreal injections to maintain vision. VIS‑101’s dual inhibition of VEGF‑A and angiopoietin‑2 targets two complementary pathways that drive neovascular leakage and fibrosis, potentially delivering more robust and longer‑lasting disease control. Early data showing >10‑letter gains and substantial retinal thickness reductions suggest the molecule may achieve efficacy comparable to current standards while extending the interval between treatments.

Clinicians have long sought therapies that lessen the treatment burden for patients, many of whom struggle with monthly or bimonthly visits. The phase 2a results indicate that a majority of patients avoided retreatment for at least four months, and half remained stable beyond six months after a three‑dose loading phase. If confirmed in larger studies, this durability could translate into fewer clinic visits, lower healthcare costs, and improved adherence, positioning VIS‑101 as a best‑in‑class candidate in the emerging class of bispecific anti‑angiogenic agents.

NovaBridge’s roadmap—advancing to a dose‑finding phase 2b later this year and a global phase 3 in 2027—aligns with regulatory expectations for progressive data packages. Investors will watch the upcoming trials for confirmatory safety signals and consistency of visual outcomes across diverse populations. Success could not only expand NovaBridge’s portfolio but also intensify competition among biotech firms developing next‑generation AMD treatments, accelerating innovation and potentially reshaping reimbursement models for chronic ocular diseases.